Lv52
910 积分 2022-02-22 加入
Post-Treatment Adverse Events Ranking in Targeted Immunotherapy for Hepatocellular Carcinoma: A Network Meta-Analysis based on Risk Probability Assessment
4天前
已完结
RNA demethylation by FTO stabilizes the FOXJ1 mRNA for proper motile ciliogenesis
9个月前
已完结
Downregulated fat mass and obesity-associated protein inhibits bone resorption and osteoclastogenesis by nuclear factor-kappa B inactivation
9个月前
已完结
1011P A prospective study of TACE combined with lenvatinib plus sintilimab for HCC with portal vein tumor thrombus
10个月前
已完结
Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma?
11个月前
已完结
Comparative efficacy and safety of molecular targeted agents combined with transarterial chemoembolization in the treatment of unresectable hepatocellular carcinoma: a network meta-analysis
11个月前
已完结
Efficacy and safety of transarterial chemoembolization plus lenvatinib in the treatment of advanced hepatocellular carcinoma: A meta-analysis
11个月前
已完结
Systemic therapy with or without locoregional therapy for advanced hepatocellular carcinoma: A systematic review and network meta-analysis
11个月前
已完结
Efficacy and safety of drug-eluting bead transarterial chemoembolization (DEB-TACE) combined with tyrosine kinase inhibitors (TKIs) in patients with unresectable hepatocellular carcinoma (uHCC): A systematic review and meta-analysis
11个月前
已完结
Lenvatinib‑based treatment regimens in conversion therapy of unresectable hepatocellular carcinoma: A systematic review and meta‑analysis
11个月前
已完结
皖公网安备34019202002308
